Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q2

2342.TEDINET S100S7OP
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥11.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥5.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥135m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥199m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥204m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥157m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥410m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥55m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥55m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥10.5bnat 2023-09-30Cons.Assets
Total assets¥10.7bnat 2023-03-31Cons.Assets
Total assets¥10.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥4.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥696m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥216m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥601m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥485m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥65m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.762023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.322022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3.262022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 32
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥111m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥153m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥187,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥92m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥246m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 493
ItemContextValueUnit
Revenues from external customersPrior1YTDDuration5542343000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember3000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember187000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember3187000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-3187000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember1268404000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember4276076000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5544481000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-2137000JPY
Net salesPrior1YTDDuration5542343000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember153476000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember92063000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember245539000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-110763000JPY
Operating incomePrior1YTDDuration134775000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember978447000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember5398402000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember6376849000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember450000JPY
Revenues from external customersCurrentYTDDuration6377299000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember3000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember628000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember3628000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-3628000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember981447000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember5399031000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember6380478000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-3178000JPY
Net salesCurrentYTDDuration6377299000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember-26609000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember223077000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember196468000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-107944000JPY
Operating incomeCurrentYTDDuration88523000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)福岡財務支局長
Filing date cover pageFilingDateInstant2023-11-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第26期第２四半期（自　2023年７月１日　至　2023年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社トランスジェニック
Company name in english cover pageFilingDateInstantTRANS GENIC INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　福永　健司
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)福岡県福岡市中央区天神二丁目３番36号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)(092)288－8470（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役　経理財務部長　　渡部　一夫
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)福岡県福岡市中央区天神二丁目３番36号
Telephone number nearest place of contact cover pageFilingDateInstant(092)288－8470
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役　経理財務部長　　渡部　一夫

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass